Your Source for Venture Capital and Private Equity Financings

Halda Therapeutics Inks $126M Series B Extension

2024-08-12
NEW HAVEN, CT, Halda Therapeutics, a biotechnology company, announced that it has raised new financing of $126 million in a Series B extension.
Halda Therapeutics, a biotechnology company developing a novel class of cancer therapies called RIPTACTM (Regulated Induced Proximity TArgeting Chimeras) therapeutics, announced that it has raised new financing of $126 million in a Series B extension, including funding from new investors Deep Track Capital, Frazier Life Sciences, RA Capital Management, Vida Ventures, Boxer Capital and Taiho Ventures, as well as existing investors Canaan Partners, Access Biotechnology, Elm Street Ventures, and Connecticut Innovations. Including this financing, Halda has raised $202 million to date from investors.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors